ATE519500T1 - Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung - Google Patents

Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung

Info

Publication number
ATE519500T1
ATE519500T1 AT02770472T AT02770472T ATE519500T1 AT E519500 T1 ATE519500 T1 AT E519500T1 AT 02770472 T AT02770472 T AT 02770472T AT 02770472 T AT02770472 T AT 02770472T AT E519500 T1 ATE519500 T1 AT E519500T1
Authority
AT
Austria
Prior art keywords
mutants
immunodeficiency virus
human immunodeficiency
envelope glycoproteins
compositions
Prior art date
Application number
AT02770472T
Other languages
English (en)
Inventor
John P Moore
James Binley
Min Lu
William Olson
Norbert Schulke
Jason Gardner
Paul Maddon
Rogier Sanders
Original Assignee
Progenics Pharm Inc
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc, Cornell Res Foundation Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of ATE519500T1 publication Critical patent/ATE519500T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT02770472T 2001-09-06 2002-09-06 Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung ATE519500T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31790901P 2001-09-06 2001-09-06
US31776401P 2001-09-06 2001-09-06
US31791001P 2001-09-06 2001-09-06
US31777501P 2001-09-06 2001-09-06
US37026402P 2002-04-05 2002-04-05
US37041002P 2002-04-05 2002-04-05
PCT/US2002/028331 WO2003022869A2 (en) 2001-09-06 2002-09-06 Human immunodeficiency virus envelope clycoprotein mutants and uses thereof

Publications (1)

Publication Number Publication Date
ATE519500T1 true ATE519500T1 (de) 2011-08-15

Family

ID=27559706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02770472T ATE519500T1 (de) 2001-09-06 2002-09-06 Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung

Country Status (7)

Country Link
US (1) US20050089526A1 (de)
EP (1) EP1461079B8 (de)
JP (1) JP2005502350A (de)
AT (1) ATE519500T1 (de)
AU (1) AU2002335709B8 (de)
CA (1) CA2459426A1 (de)
WO (1) WO2003022869A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
EP1496938A4 (de) * 2002-04-05 2006-10-04 Progenics Pharm Inc Partikelgebundene humane immunschwäche-virus-hüll-glykoproteine und verwandte zusammensetzungen und verfahren
GB0228939D0 (en) * 2002-12-12 2003-01-15 Univ Nottingham Peptide presentations for human immunodeficiency disease vaccines
EP1706513A4 (de) * 2003-11-26 2007-12-26 Tanox Inc Human-immundefizienz-virus-entry-inhibitor-assay
US7964196B2 (en) * 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
WO2006002079A2 (en) * 2004-06-15 2006-01-05 Progenics Pharmaceuticals, Inc. Hiv-1 neutralizing antibodies elicited by trimeric hiv-1 envelope glycoprotein complex
EP2088155A1 (de) 2004-12-29 2009-08-12 Seattle Biomedical Research Institute Hetero-oligomere HIV-Hüllproteine
JP2009533350A (ja) * 2006-04-07 2009-09-17 キメロス， インコーポレイテッド Ｂ細胞悪性疾患を処置するための組成物および方法
WO2007149490A1 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
EP2040747A4 (de) * 2006-06-19 2010-08-25 Progenics Pharm Inc Lösliche stabilisierte trimere hiv-hüllproteine und ihre verwendung
EP2073840A4 (de) * 2006-10-23 2010-10-27 Progenics Pharm Inc Modifizierte gp140-hüllpolypeptide von hiv-1-isolaten, zusammensetzungen, stabilisierten trimeren komplexen und ihre verwendungen
US20090226525A1 (en) * 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
CA2687024A1 (en) * 2007-05-09 2009-02-19 Burnham Institute For Medical Research Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
EP2476753A4 (de) * 2009-09-09 2013-10-09 Tokyo Inst Tech Mit einem eine virusbeschichtung bildenden protein beschichteter artikel und verfahren zu seiner herstellung
WO2012003234A2 (en) * 2010-06-30 2012-01-05 Torrey Pines Institute For Molecular Studies Env trimer immunogens
US10675346B2 (en) 2010-11-12 2020-06-09 Children's Medical Center Corporation Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41
JP6407714B2 (ja) * 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型ｈｉｖエンベロープタンパク質（ｅｎｖ）、前記に関連する方法及び組成物
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
EP2765138B1 (de) * 2012-11-05 2018-01-10 International Aids Vaccine Initiative Hüllglykoprotein von HIV-1
HK1219109A1 (zh) * 2013-03-15 2017-03-24 麦克法兰布奈特医疗研究与公共健康研究所有限公司 免疫原性组合物及其产生方法
WO2015127108A1 (en) * 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
MY200554A (en) * 2017-07-19 2024-01-03 Janssen Vaccines & Prevention Bv Trimer stabilizing hiv envelope protein mutations
US11590219B2 (en) 2018-01-30 2023-02-28 Emory University Compositions and methods for promoting immune responses to human immunodeficiency virus
CN114127305A (zh) 2019-05-23 2022-03-01 麻省理工学院 经由逆转录病毒表面展示的配体发现和基因递送
WO2020243166A1 (en) * 2019-05-28 2020-12-03 The Regents Of The University Of California Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens
WO2022100703A1 (zh) 2020-11-12 2022-05-19 厦门大学 经改造的人免疫缺陷病毒膜蛋白及其应用
EP4784626A1 (de) 2023-09-25 2026-08-05 Kelonia Therapeutics, Inc. Antigenbindende polypeptide
IL327310A (en) 2023-09-25 2026-05-01 Kelonia Therapeutics Inc Cancer treatment vehicles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT62316A (en) * 1990-09-25 1993-04-28 Hiver Ltd Process for producing aids vaccine and for diagnosing aids
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5674698A (en) * 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US6171596B1 (en) * 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US6716429B1 (en) * 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
WO2001000648A1 (en) * 1999-06-25 2001-01-04 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
EP1496938A4 (de) * 2002-04-05 2006-10-04 Progenics Pharm Inc Partikelgebundene humane immunschwäche-virus-hüll-glykoproteine und verwandte zusammensetzungen und verfahren
US7901690B2 (en) * 2002-12-03 2011-03-08 University Of Massachusetts Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US7737067B2 (en) * 2005-12-20 2010-06-15 Chevron U.S.A. Inc. Regeneration of ionic liquid catalyst

Also Published As

Publication number Publication date
JP2005502350A (ja) 2005-01-27
AU2002335709B8 (en) 2008-12-18
CA2459426A1 (en) 2003-03-20
WO2003022869A2 (en) 2003-03-20
US20050089526A1 (en) 2005-04-28
EP1461079A4 (de) 2006-09-20
AU2002335709B2 (en) 2008-11-27
WO2003022869A3 (en) 2004-07-22
EP1461079A2 (de) 2004-09-29
EP1461079B8 (de) 2012-03-14
EP1461079B1 (de) 2011-08-10

Similar Documents

Publication Publication Date Title
EP1461079A4 (de) Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
ATE267211T1 (de) Impfstoff gegen hpv
DE60225118D1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
ATE231917T1 (de) Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
ATE328068T1 (de) Papillomavirus vakzine
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
ES2150595T3 (es) Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
DE60037450D1 (de) Funf-helix protein
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
DE59410380D1 (de) Endosomolytisch wirksame partikel
PL363071A1 (pl) Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
IL149459A0 (en) Recombinant gelatins
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
ATE356207T1 (de) Humanes btrcp protein
EP1578772A4 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
MX2025007937A (es) Proteinas 3 f del virus de la parainfluenza humana estabilizadas prefusion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties